Literature DB >> 32364539

Insulin-stimulated lipogenesis gets an epigenetic makeover.

Clarence R Manuel, Rebecca A Haeusler.   

Abstract

Hepatic de novo lipogenesis is a major contributor to nonalcoholic fatty liver disease (NAFLD). In this issue of the JCI, Liu and Lin et al. identified Slug as an epigenetic regulator of lipogenesis. Their findings suggest that Slug is stabilized by insulin signaling, and that it promotes lipogenesis by recruiting the histone demethylase Lsd1 to the fatty acid synthase gene promoter. On the other hand, genetic deletion or acute depletion of Slug, or Lsd1 inhibition, reduced lipogenesis and protected against obesity-associated NAFLD and insulin resistance in mice. This study advances our understanding of how lipogenesis is regulated downstream of insulin signaling in health and disease.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32364539      PMCID: PMC7260037          DOI: 10.1172/JCI137050

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  11 in total

Review 1.  Histone Lysine Demethylase Inhibitors.

Authors:  Ashwini Jambhekar; Jamie N Anastas; Yang Shi
Journal:  Cold Spring Harb Perspect Med       Date:  2017-01-03       Impact factor: 6.915

2.  Hepatic Slug epigenetically promotes liver lipogenesis, fatty liver disease, and type 2 diabetes.

Authors:  Yan Liu; Haiyan Lin; Lin Jiang; Qingsen Shang; Lei Yin; Jiandie D Lin; Wen-Shu Wu; Liangyou Rui
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

3.  Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease.

Authors:  Nishanth E Sunny; Elizabeth J Parks; Jeffrey D Browning; Shawn C Burgess
Journal:  Cell Metab       Date:  2011-12-07       Impact factor: 27.287

4.  Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease.

Authors:  Jennifer E Lambert; Maria A Ramos-Roman; Jeffrey D Browning; Elizabeth J Parks
Journal:  Gastroenterology       Date:  2013-12-04       Impact factor: 22.682

Review 5.  NAFLD and diabetes mellitus.

Authors:  Herbert Tilg; Alexander R Moschen; Michael Roden
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-10-12       Impact factor: 46.802

6.  Histone demethylation mediated by the nuclear amine oxidase homolog LSD1.

Authors:  Yujiang Shi; Fei Lan; Caitlin Matson; Peter Mulligan; Johnathan R Whetstine; Philip A Cole; Robert A Casero; Yang Shi
Journal:  Cell       Date:  2004-12-29       Impact factor: 41.582

Review 7.  Transcriptional regulation of hepatic lipogenesis.

Authors:  Yuhui Wang; Jose Viscarra; Sun-Joong Kim; Hei Sook Sul
Journal:  Nat Rev Mol Cell Biol       Date:  2015-11       Impact factor: 94.444

8.  Histone demethylase JMJD1C is phosphorylated by mTOR to activate de novo lipogenesis.

Authors:  Jose A Viscarra; Yuhui Wang; Hai P Nguyen; Yoon Gi Choi; Hei Sook Sul
Journal:  Nat Commun       Date:  2020-02-07       Impact factor: 14.919

9.  Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors.

Authors:  Rebecca A Haeusler; Kirsten Hartil; Bhavapriya Vaitheesvaran; Isabel Arrieta-Cruz; Colette M Knight; Joshua R Cook; Helene L Kammoun; Mark A Febbraio; Roger Gutierrez-Juarez; Irwin J Kurland; Domenico Accili
Journal:  Nat Commun       Date:  2014-10-13       Impact factor: 14.919

10.  Insulin/Snail1 axis ameliorates fatty liver disease by epigenetically suppressing lipogenesis.

Authors:  Yan Liu; Lin Jiang; Chengxin Sun; Nicole Ireland; Yatrik M Shah; Yong Liu; Liangyou Rui
Journal:  Nat Commun       Date:  2018-07-16       Impact factor: 14.919

View more
  2 in total

Review 1.  Interplay Among Metabolism, Epigenetic Modifications, and Gene Expression in Cancer.

Authors:  Miaomiao Huo; Jingyao Zhang; Wei Huang; Yan Wang
Journal:  Front Cell Dev Biol       Date:  2021-12-24

2.  Synergistic effects of ISL1 and KDM6B on non-alcoholic fatty liver disease through the regulation of SNAI1.

Authors:  Fei Zhao; Jinjing Ke; Wensheng Pan; Hanghai Pan; Miao Shen
Journal:  Mol Med       Date:  2022-01-31       Impact factor: 6.354

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.